Most infections are caused by bacteria on the patient's skin entering the surgical wound. Scientists in the U.S. have devised an implant in a tiny silk 'purse' that kills infections after surgery and then dissolves in the body. Up to four in 100 people undergoing surgery in the UK will develop an infection, and this can prolong hospital stays by as much as nine days. Surgical wound infections are the leading cause of hospital readmissions after operations, according to a study published last month. Most infections are caused by bacteria on the patient's skin entering the surgical wound. The most common culprits are Staphylococcus aureus bacteria, responsible for 20 per cent of surgical site infections, coagulase negative staphylococcus, and enterococcus bacteria. The infection can usually be treated with antibiotics but sometimes patients need more complex treatment, including further surgery. The new implant uses heat to kill off bacteria. It consists of a tiny, magnesium coil wrapped in a pocket of silk protein, and is implanted during surgery - if the patient later shows sign of infection, the implant can be switched on using a remote control. This raises the temperature of the coil. The silk protein protects the coil - both harmlessly dissolve in the body over the next fortnight. This is an improvement on previous medical implant devices, which are made from non-degradable materials that need to be removed. Researchers at Tufts University have used the implant in mice infected with Staphylococcus aureus, raising its temperature for two periods of ten minutes. Within 24 hours the tissue was infection-free. The device, including the coil, completely dissolved after 15 days. 'This is an important step forward for the development of on-demand medical devices that can be turned on remotely,' the researchers said. 'These wireless strategies could help manage post-surgical infection, for example, or pave the way for eventual "wi-fi" drug delivery.' The team has also carried out experiments using remote control to deliver antibiotics to treat E.coli and Staphylococcus aureus. Stella Vig, consultant vascular and general surgeon at Croydon University Hospital, said: 'This is an exciting new concept and an innovative tool against the war of surgical site infection. This new purse could allow a reduction of bacterial load with an implantable device. The concept of reducing bacterium within the tissues and thereby reducing risk of infections is not new, and was previously achieved by deploying antibiotic beads within the tissues. These required retrieval and therefore are not used routinely. 'This new device would allow a reduction of bacterial load with an implantable device, which then disappears without the need for surgery to remove it. 'Surgical site infections are costly as they increase the length of stay for patients and can lead to further surgery.' Meanwhile, a team at the University of South Florida has developed a new antibiotic to fight the superbug methicillin-resistant Staphylococcus aureus or MRSA, which kills thousands of people worldwide each year. The bug is a form of Staphylococcus aureus which does not respond to the usual antibiotics. The new treatment is based on a class of drugs called quinazolines, which have been used in treating malaria and cancer. They have recently been shown to act on bacteria, too. 'In recent years, MRSA has become resistant to vancomycin, our most valuable treatment option against staphylococcal infections,' said Dr Lindsey N. Shaw, whose team developed the new drugs. 'Bacterial disease remains the second-leading cause of death globally, especially among children and the elderly. 'We need new drugs to fight these infections.'
Summarize the highlights of this article.
Surgical wound infections are the leading cause of hospital readmissions.
New tiny silk 'purse' that kills infections after surgery is being trialled.
Has been used successfully in mice infected with Staphylococcus aureus.
De flesta infektioner orsakas av bakterier på patientens hud som kommer in i operationssåret. Vetenskapsmän i USA har hittat på ett implantat i en liten silkesväska som dödar infektioner efter operation och sedan löser upp sig i kroppen. Upp till fyra av 100 personer som genomgår kirurgi i Storbritannien kommer att utveckla en infektion, och detta kan förlänga sjukhusvistelser med så mycket som nio dagar. Kirurgiska sårinfektioner är den främsta orsaken till sjukhusåtertagningar efter operationer, enligt en studie som publicerades förra månaden. De flesta infektioner orsakas av bakterier på patientens hud som kommer in i operationssåret. De vanligaste bovarna är Staphylococcus aureus-bakterier, som svarar för 20 procent av infektionerna på operationsstället, koagulasnegativa stafylokocker och enterococcus-bakterier. Infektionen kan oftast behandlas med antibiotika men ibland behöver patienter mer komplex behandling, inklusive ytterligare kirurgi. Det nya implantatet använder värme för att döda bakterier. Den består av en liten, magnesium spole inlindad i en ficka av silkesprotein, och implanteras under operation - om patienten senare visar tecken på infektion, kan implantatet slås på med hjälp av en fjärrkontroll. Detta höjer temperaturen på spolen. Sidenproteinet skyddar spolen - båda löser sig ofarligt i kroppen under de kommande fjorton dagarna. Detta är en förbättring jämfört med tidigare medicintekniska implantat, som är gjorda av icke-nedbrytbara material som måste avlägsnas. Forskare vid Tufts University har använt implantatet i möss som infekterats med Staphylococcus aureus, vilket höjer dess temperatur i två perioder på tio minuter. Inom 24 timmar var vävnaden infektionsfri. Apparaten, inklusive spolen, upplöstes helt efter 15 dagar. "Detta är ett viktigt steg framåt för utvecklingen av medicintekniska produkter på begäran som kan aktiveras på distans", sade forskarna. "Dessa trådlösa strategier kan bidra till att hantera postkirurgisk infektion, till exempel, eller bana väg för eventuell "wi-fi" drogleverans. " Teamet har även utfört experiment med hjälp av fjärrkontroll för att leverera antibiotika för att behandla E.coli och Staphylococcus aureus. Stella Vig, konsult kärl- och generalkirurg vid Croydon University Hospital, sade: "Detta är ett spännande nytt koncept och ett innovativt verktyg mot kriget av kirurgisk infektion. Denna nya handväska skulle kunna möjliggöra en minskning av bakteriebelastningen med en implanterbar anordning. Konceptet att minska bakterien i vävnaderna och därmed minska risken för infektioner är inte nytt, och uppnåddes tidigare genom att sprida antibiotikapärlor i vävnaderna. Dessa krävde hämtning och används därför inte rutinmässigt. Den här nya apparaten skulle göra det möjligt att minska bakteriebelastningen med en implanterbar apparat, som sedan försvinner utan att behöva opereras bort. "Surgiska infektioner är dyra eftersom de ökar längden på vistelse för patienter och kan leda till ytterligare operation. " Samtidigt har ett team vid University of South Florida utvecklat ett nytt antibiotikum för att bekämpa superb meticillinresistenta Staphylococcus aureus eller MRSA, som dödar tusentals människor världen över varje år. Buggen är en form av Staphylococcus aureus som inte svarar på de vanliga antibiotika. Den nya behandlingen bygger på en klass av läkemedel som kallas kinazoliner, som har använts vid behandling av malaria och cancer. De har nyligen visat sig verka på bakterier också. "På senare år har MRSA blivit resistent mot vancomycin, vårt mest värdefulla behandlingsalternativ mot stafylokockinfektioner," sade Dr Lindsey N. Shaw, vars team utvecklat de nya läkemedlen. "Bakteriell sjukdom är fortfarande den näst vanligaste dödsorsaken globalt, särskilt bland barn och äldre. "Vi behöver nya läkemedel för att bekämpa dessa infektioner." Sammanfatta höjdpunkterna i den här artikeln.
Most infections are caused by bacteria on the patient’s skin that enter the surgical wound. Scientists in the United States have invented an implant in a small silk bag that kills infections after surgery and then dissolves in the body. Up to four out of 100 people undergoing surgery in the UK will develop an infection, and this may extend hospitalizations by as much as nine days. Surgical wound infections are the main cause of post-operative hospital withdrawals, according to a study published last month. Most infections are caused by bacteria on the patient’s skin that enter the surgical wound. The most common culprits are Staphylococcus aureus bacteria, which account for 20% of the infections at the site of surgery, coagulase-negative staphylococci and enterococcus bacteria. The infection can usually be treated with antibiotics but sometimes patients need more complex treatment, including additional surgery. The new implant uses heat to kill bacteria. It consists of a small, magnesium coil wrapped in a pocket of silk protein, and implanted during surgery - if the patient later shows signs of infection, the implant can be switched on using a remote control. This increases the temperature of the coil. The silk protein protects the coil - both dissolve harmlessly in the body over the next fourteen days. This is an improvement on previous medical implants, which are made of non-degradable materials that must be removed. Researchers at Tufts University have used the implant in mice infected with Staphylococcus aureus, raising its temperature for two periods of ten minutes. Within 24 hours, the tissue was free of infection. The device, including the coil, completely disbanded after 15 days. "This is an important step forward for the development of on-demand medical devices that can be activated remotely," the researchers said. "These wireless strategies can help manage post-surgical infection, for example, or pave the way for any "wi-fi" drug delivery." The team has also conducted experiments using remote control to deliver antibiotics to treat E.coli and Staphylococcus aureus. Stella Vig, a consultant vascular and general surgeon at Croydon University Hospital, said: "This is an exciting new concept and an innovative tool against the war of surgical infection. This new purse could allow for a reduction in bacterial load with an implantable device. The concept of reducing bacteria in the tissues and thus reducing the risk of infections is not new, and was previously achieved by spreading antibiotic beads into the tissues. These required retrieval and are therefore not routinely used. This new device would make it possible to reduce bacterial loads with an implantable device, which then disappears without having to be removed. "Surgical infections are expensive because they increase the duration of stay for patients and can lead to further surgery." At the same time, a team at the University of South Florida has developed a new antibiotic to fight superb methicillin-resistant Staphylococcus aureus or MRSA, which kills thousands of people worldwide each year. The bug is a form of Staphylococcus aureus that does not respond to the usual antibiotics. The new treatment is based on a class of medicines called quinazolins, which have been used in the treatment of malaria and cancer. They have recently been shown to act on bacteria as well. "In recent years, MRSA has become resistant to vancomycin, our most valuable treatment option for staphylococcal infections," said Dr. Lindsey N. Shaw, whose team developed the new drugs. "Bacterial disease remains the second most common cause of death globally, especially among children and the elderly. "We need new drugs to fight these infections." Summarize the highlights of this article.
Kirurgiska sårinfektioner är den främsta orsaken till sjukhusåtertagningar. Ny liten silkespung som dödar infektioner efter operation prövas. Har använts framgångsrikt hos möss infekterade med Staphylococcus aureus.
Surgical wound infections are the main cause of hospital recovery. New small silk plunge that kills infections after surgery is being tried. Has been successfully used in mice infected with Staphylococcus aureus.